Oxford-based OxSonics Therapeutics announced that the first patient was dosed in a clinical trial evaluating their SonoTran platform for treating colorectal cancer that has spread to the liver.
The SonoTran platform is designed to actively pump unmodified oncology drugs at the site of solid tumors to enhance their effectiveness.
Nearly 50 patients with liver metastases will be enrolled at Oxford University Hospitals.
The Foundation seeks to fund cancer immunotherapy projects that address focused ultrasound’s effects on the tumor vasculature or partial versus total tumor ablation outcomes.
Clinical phase 1 or window-of-opportunity trials combining focused ultrasound with an immunotherapeutic are also of interest.
OxSonics Therapeutics is a clinical-stage oncology company that has developed an ultrasound-based drug delivery platform.
Their SonoTran Platform uses low-intensity focused ultrasound combined with injectable ‘SonoTran Particles’ to enhance the dose and penetration of unmodified cancer drugs into solid tumors.
The Society for Thermal Medicine (STM) will hold its 2022 Virtual Annual Meeting May 1-4, 2022. Registration is open, and the deadline for abstract submission is February 1.
